Hexamer Therapeutics, Inc
New Form D on file · 2026-09-15 · the record
What the record says
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 570 filings in Biotechnology, totalled by week. The dot is this raise, $500K, on the same scale — one filing against the whole group's total, so it sits low by construction.
Checked away from the filing. What is below does not come from the record on sec.gov.
Innovators in natural vaccine technology. Explore rapidly engineered, scalable vaccine technologies at Hexamer Therapeutics.
The title and description the site itself served, answering 200, after redirecting from https://hexamertherapeutics.com. Not a cached copy and not the company's directory entry — what was live when we asked.
Company officers on record
Robert Bogden is named as Executive Officer and Director on the Form D that Hexamer Therapeutics, Inc filed with the SEC on 15 September 2026, one of 6 people that filing names.
Colin Collins is named as Director on the Form D that Hexamer Therapeutics, Inc filed with the SEC on 15 September 2026, one of 6 people that filing names.
Keith Miller is named as Director on the Form D that Hexamer Therapeutics, Inc filed with the SEC on 15 September 2026, one of 6 people that filing names.
R. Scott Blackley is named as Director on the Form D that Hexamer Therapeutics, Inc filed with the SEC on 15 September 2026, one of 6 people that filing names.
Stephen Crawford is named as Director on the Form D that Hexamer Therapeutics, Inc filed with the SEC on 15 September 2026, one of 6 people that filing names.
Brad Call is named as Director on the Form D that Hexamer Therapeutics, Inc filed with the SEC on 15 September 2026, one of 6 people that filing names.
6 people named on the filing — 1 holding an executive role and 5 as directors only.
Named as of the 2026-09-15 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
- 6 people named on the filing — 1 holding an executive role and 5 as directors only.
No investor is drawn from a Form D — the form states how many invested and never who.
The full profile
Source Check, INVEST, RECRUIT and Press Requests on Hexamer Therapeutics, Inc
- Source Check — verify Robert H. Bogden's other claims against the registers that hold them.
- INVEST — size up this raise on the figures the filing states.
- RECRUIT — see who is already on the team.
- Press Requests — connect with Robert H. Bogden for a story.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Hexamer Therapeutics, IncYou get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind Hexamer Therapeutics, Inc: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. FoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-09-25 (hexamertherapeutics.com).